Media Coverage

Thomas J. Guttuso Jr., MD, associate professor of neurology and obstetrics and gynecology, will test the effectiveness of the anticonvulsant drug gabapentin in treating hyperemesis gravidarum, a rare but disabling condition of early pregnancy.

According to Michael G. Dwyer III, PhD, assistant professor of neurology, reductions in brain volume often seen in patients with chronic relapsing-remitting multiple sclerosis may be reduced by treatment with interferon beta-1a.

Kinga Szigeti, MD, PhD, assistant professor of neurology and director of the University at Buffalo Alzheimer‘s Disease and Memory Disorders Center, provides insight about dementia and Alzheimer's, and notes that “genetics is a very useful tool to crack this disease.” 

Arie L. Weinstock, MD, of the Department of Neurology, provides insight about a genetic disease affecting cell growth in the nervous system. Neurofibromatosis can cause learning disabilities, disfigurement, blindness, headaches, seizures, hearing loss and “excruciating, disabling neuropathic pain,” he says.

Robert Zivadinov, MD, PhD, professor of neurology, says that although multiple sclerosis has been considered an inflammatory demyelinating disease affecting the white matter of the central nervous system, recent studies have established that gray matter is also involved in different stages of the disease.

Albany Molecular Research Inc. will be up and running in a temporary space within the Jacobs Neurological Institute — home to the University at Buffalo’s Department of Neurology — on the Buffalo Niagara Medical Campus, the future site of the new UB medical school.

Along with his colleagues, Robert Zivadinov, MD, PhD, professor of neurology and director of UB’s Buffalo Neuroimaging Analysis Center, is calling for more investigation into how venous abnormalities in the neck might be involved in central nervous system disorders and aging.

Robert Zivadinov, MD, PhD, professor of neurology, has contributed to research that shows low Vitamin D levels in multiple sclerosis patients may signal a progression of the disease.

Results of a small, randomized trial led by Robert Zivadinov, MD, PhD, professor of neurology, added to the controversy surrounding a multiple sclerosis treatment to correct chronic cerebrospinal venous insufficiency — among the top Canadian news topics in 2013.

Lead investigator Robert Zivadinov, MD, PhD, professor of neurology, discusses the surprising findings of a pilot trial which showed a treatment to correct chronic cerebrospinal venous insufficiency did not benefit multiple sclerosis patients.